AIHealthcare

Diagens Tech, legally Hangzhou Diagens Biotechnology Co., Ltd., is a China-based medical-imaging and AI healthcare company. Its offerings span AI-assisted chromosome karyotype analysis, automated cell-imaging equipment, medical-imaging software and devices, and technology licensing through its iMedMaaS platform. Its proprietary iMedImage medical-imaging foundation model underpins a model-as-a-service strategy for hospitals, research institutions, and other healthcare technology customers. The company states that its systems are used across genetics health, hematologic oncology, and radiological-health applications. It listed on the Hong Kong Stock Exchange in March 2026 (ticker: 02526), raising approximately US$101 million in its IPO. Independent transaction reporting cited it as the largest company by 2024 revenue share in China’s chromosome-karyotype-analysis-system market; reported company materials say its products were deployed in more than 400 healthcare centers and institutions in China. These market-position claims should be treated as reported rather than independently audited here.